AstraZeneca Stock - Analyst sentiment and chart picture on Thursday

AstraZeneca stock trades lower in London on Thursday while remaining a consensus Buy. Analyst targets imply further upside, and the AZN chart sits near key levels as investors track the pharma group's late-stage pipeline and oncology focus.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 16:20 UTC. Details in the imprint.

AstraZeneca (GB0009895292) is one of Europe's largest pharmaceutical groups and remains a heavyweight in global healthcare indices. On Thursday the focus is on analyst sentiment and the technical chart picture rather than on a fresh corporate announcement.

What analysts are signaling

Across major data providers, AstraZeneca stock carries a consensus rating of Buy, underlining robust confidence in the pipeline and earnings outlook. Average 12-month price targets typically sit meaningfully above current trading levels, implying double-digit percentage upside potential.

For example, one aggregated view cites a consensus target around 234 in local currency terms for the US line, compared with a recent US close near $177.89 for the AZN ticker. That gap illustrates how the analyst community still sees room for appreciation despite recent volatility.

Chart levels on a Thursday

On the London Stock Exchange, AstraZeneca shares recently changed hands around GBP 131.48, with the quote on Thursday showing a decline of roughly 2.3% compared with the prior close. That puts the stock below recent short-term peaks but still well above its 52-week low.

In the US, AstraZeneca trades on Nasdaq under the AZN ticker, with the last available close around $177.89 on 06/17/2026. This level reflects a modest pullback from recent highs while keeping the broader uptrend from earlier in the year largely intact.

What the company sells

AstraZeneca generates most of its revenue from prescription medicines, with a particular emphasis on oncology, cardiovascular, renal and metabolism, and respiratory diseases. Flagship products include the lung-cancer drug Tagrisso and the oncology therapy Imfinzi, both key profit drivers in recent years.

Where the stock trades today

As of 06/18/2026, 16:05 UTC, AstraZeneca shares (GB0009895292) trade on the London Stock Exchange at about GBP 131.48 and on Nasdaq at roughly $177.89.

Key facts on AstraZeneca stock

• Company: AstraZeneca PLC
• ISIN: GB0009895292
• WKN: 886455
• Ticker: AZN
• Venue: London Stock Exchange / Nasdaq
• Price (as of 06/18/2026, 16:05 UTC): 131.48 GBP / 177.89 USD
• Market cap: 551.78 billion USD (as of 06/17/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: FTSE 100, listed as ADR on major US indices
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.